期刊文献+

辛伐他汀对颈动脉粥样硬化的影响 被引量:3

Influence of simvastatin on carotid atherosclerosis
下载PDF
导出
摘要 目的探讨辛伐他汀对颈动脉内膜-中膜厚度及颈动脉粥样硬化斑块的影响。方法用彩色多普勒超声技术,检测出具有不同程度的颈动脉粥样硬化患者48例,给予辛伐他汀20mg每晚口服,共3个月。观察患者治疗前后颈动脉内膜-中膜厚度、颈动脉粥样硬化斑块面积的变化以及血脂水平、丙氨酸转换酶、肌酸激酶的变化和药物不良反应。结果全部患者治疗前共有79个斑块,治疗后54个斑块,斑块消失率32%,其余未消失的斑块面积均有明显缩小(P<0.01);颈动脉内膜-中膜厚度明显缩小(P<0.01),TC、TG、LDL-C明显下降(P<0.01),HDL-C升高(P<0.05),ALT、CK无变化(P>0.05),无明显不良反应。结论彩色多普勒超声能检测出早期颈动脉粥样硬化。辛伐他汀能稳定和消退粥样斑块,调脂疗效确切,从而减少心脑血管事件的发生。 Objective To investigate the influences of simvastatin on carotid artery Intima-media thickness(IMT)and carotid atherosclerotic plaque. Methods 48 patients with different degrees carotid atherosclerosis detected by ultrasonic received simvastatin 20mg per night for 3 months. The carotid artery IMT and carotid atherosclerotic plaques were detected before and after treatment, as well as lipid levels, ALT and CK was determined . The side effects of simvastatin were observed. Results There were 79 plaques in all patients. After 3 months of treatment with simvastatin, 25 plaques vanished respectively and the size of the other 54 plaques decreased significantly(P〈0.01) ,IMT decreased significantly(P〈0.01). The levels of TC, TG and LDL-C decreased significantly(P〈0.01) ,HDL-C increased(P〈0.05). There were no changes in ALT and CK and no side effects of simvastatin during treatment. Conclusion Simvastatin can decline the carotid atherosclerotic plaque, lower serum lipid effectively, and then decrease the rates of cardiovascular and cerebrovascular events.
出处 《中国实用神经疾病杂志》 2007年第6期13-14,共2页 Chinese Journal of Practical Nervous Diseases
关键词 辛伐他汀 颈动脉粥样硬化 内膜-中膜厚度 斑块 超声检查 Simvastatin Carotid atherosclerosis Intima-media thickness Plaque Ultrasonography
  • 相关文献

参考文献9

二级参考文献60

  • 1周青,郭瑞强,郝力丹.高频超声评价冠状动脉狭窄与颈动脉内-中膜厚度及面积的关系[J].中国超声医学杂志,2003,19(11):828-830. 被引量:30
  • 2各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33020
  • 3[1]Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowing with simvastatin in 20536high-risk individuals: a randomized placebo-controlled trial.Lancet, 2002, 360:7-22.
  • 4[2]Cox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation, 2004,109: Ⅱ 42- Ⅱ 48.
  • 5[3]Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J,2003, 24: 225-248.
  • 6[4]Backes JM, Howard PA, Moriarty PM. Role of C-reactive protein in cardiovascular disease. Ann Pharmacother, 2004, 38:110-118.
  • 7[5]Horne BD, Muhlestein JB, Carlquist JF, et al. Intermountain Heart Collaborative (IHC) Study Group. Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation, 2003,107: 258-263.
  • 8[6]Gupta S. Does aggressive statin therapy offer improved cholesterol-independent benefits compared to conventional statin treatment? Int J Cardiol, 2004, 96:131-139.
  • 9[7]Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med, 2005,352: 20-28.
  • 10[8]Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy,LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med, 2005, 352:29-38.

共引文献344

同被引文献6

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部